5,6-diiodo-1H-benzotriazole: new TBBt analogue that minutely affects mitochondrial activity

Area of Science:

• Biochemistry
• Medicinal Chemistry
• Molecular Biology

Background:

• Protein kinase CK2 (hCK2α) is a key target for cancer therapy.
• 4,5,6,7-Tetrabromo-1H-benzotriazole (TBBt) is a well-established CK2 inhibitor.
• Development of novel CK2 inhibitors with improved profiles is needed.

Purpose of the Study:

• To synthesize and characterize novel halogenated benzotriazole analogs.
• To evaluate the inhibitory potential of these analogs against hCK2α.
• To assess their biological activity, including cytotoxicity and mitochondrial effects.

Main Methods:

• Synthesis of 5,6-diiodo- and 5,6-diiodo-4,7-dibromo-1H-benzotriazole.
• Biophysical methods: MicroScale Thermophoresis (MST) and Isothermal Titration Calorimetry (ITC).
• Biochemical assays: enzymatic activity and cytotoxicity assays against cancer cell lines.

Main Results:

• Both iodinated compounds effectively inhibit hCK2α.
• One analog demonstrated comparable cytotoxicity to TBBt against cancer cell lines.
• The lead iodinated compound showed reduced impact on mitochondrial inner membrane potential compared to TBBt.

Conclusions:

• Iodinated benzotriazoles represent a viable alternative to brominated CK2 inhibitors.
• The studied compounds are promising candidates for further development as hCK2α-targeted cancer therapeutics.
• Optimized halogenated benzotriazoles may offer a better therapeutic window for CK2 inhibition.